DK2854789T3 - Genotype- eller fænotype-baserede lægemiddelformuleringer - Google Patents
Genotype- eller fænotype-baserede lægemiddelformuleringer Download PDFInfo
- Publication number
- DK2854789T3 DK2854789T3 DK13725157.5T DK13725157T DK2854789T3 DK 2854789 T3 DK2854789 T3 DK 2854789T3 DK 13725157 T DK13725157 T DK 13725157T DK 2854789 T3 DK2854789 T3 DK 2854789T3
- Authority
- DK
- Denmark
- Prior art keywords
- genotype
- phenotype
- pharmaceutical formulations
- based pharmaceutical
- formulations
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12170401.9A EP2668945A1 (de) | 2012-06-01 | 2012-06-01 | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
PCT/EP2013/060824 WO2013178565A1 (de) | 2012-06-01 | 2013-05-27 | Genotyp- bzw. phänotyp-basierte arzeimittelformulierungen |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2854789T3 true DK2854789T3 (da) | 2019-09-16 |
Family
ID=48520964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13725157.5T DK2854789T3 (da) | 2012-06-01 | 2013-05-27 | Genotype- eller fænotype-baserede lægemiddelformuleringer |
Country Status (23)
Country | Link |
---|---|
US (3) | US10285958B2 (da) |
EP (2) | EP2668945A1 (da) |
JP (2) | JP6096289B2 (da) |
KR (1) | KR102129043B1 (da) |
CN (2) | CN104507464A (da) |
AR (2) | AR091234A1 (da) |
AU (1) | AU2013269793B2 (da) |
BR (1) | BR112014030059B1 (da) |
CA (1) | CA2875189C (da) |
DK (1) | DK2854789T3 (da) |
ES (1) | ES2744306T3 (da) |
HK (1) | HK1207296A1 (da) |
HU (1) | HUE045699T2 (da) |
IL (1) | IL235988B (da) |
MX (1) | MX370304B (da) |
NZ (1) | NZ702849A (da) |
PL (1) | PL2854789T3 (da) |
PT (1) | PT2854789T (da) |
RU (1) | RU2683260C2 (da) |
SA (1) | SA113340607B1 (da) |
SG (2) | SG10201610072UA (da) |
TW (1) | TWI644666B (da) |
WO (1) | WO2013178565A1 (da) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2668945A1 (de) * | 2012-06-01 | 2013-12-04 | Bayer Technology Services GmbH | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
US11965206B2 (en) | 2018-12-21 | 2024-04-23 | John Stoddard | Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1317546C (en) | 1985-07-01 | 1993-05-11 | Werner Meier | Pharmaceutical preparations containing mixtures of hydroxy derivatives of vitamin d |
US6048857A (en) | 1989-10-17 | 2000-04-11 | Ellinwood, Jr.; Everett H. | Dosing method of administering medicaments via inhalation administration |
US5580728A (en) | 1994-06-17 | 1996-12-03 | Perlin; Mark W. | Method and system for genotyping |
US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
US6760708B1 (en) | 1999-08-19 | 2004-07-06 | Dell Products L.P. | Method and system for migrating stored data to a build-to-order computing system |
AU2001231091A1 (en) | 2000-01-21 | 2001-07-31 | Vincent P. Stanton Jr. | Identification of genetic components of drug response |
US7427480B2 (en) | 2002-03-26 | 2008-09-23 | Perlegen Sciences, Inc. | Life sciences business systems and methods |
AU2004270150C1 (en) * | 2003-08-29 | 2011-07-14 | Merck Hdac Research, Llc | Combination methods of treating cancer |
US7504214B2 (en) * | 2003-09-19 | 2009-03-17 | Biotheranostics, Inc. | Predicting outcome with tamoxifen in breast cancer |
DE10345836A1 (de) | 2003-10-02 | 2005-04-21 | Bayer Technology Services Gmbh | Verfahren zur Simulation der Wechselwirkung von chemischen Substanzen mit lebenden Organismen |
JP4732683B2 (ja) | 2003-12-29 | 2011-07-27 | ユニバーサル・バイオ・リサーチ株式会社 | 標的物質の検出方法 |
US7169813B2 (en) | 2004-03-18 | 2007-01-30 | Fondazione IRCCS “Istituto Nazionale Dei Tumori” | 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer |
US7805282B2 (en) | 2004-03-30 | 2010-09-28 | New York University | Process, software arrangement and computer-accessible medium for obtaining information associated with a haplotype |
DE102004025534A1 (de) | 2004-05-25 | 2005-12-15 | Bayer Technology Services Gmbh | Verfahren zur (zweistufigen) Dosis- und Dosierungsfindung |
US8024128B2 (en) | 2004-09-07 | 2011-09-20 | Gene Security Network, Inc. | System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data |
US8147615B2 (en) | 2004-11-05 | 2012-04-03 | Infineon Technologies Ag | Method of fabricating semiconductor cleaners |
WO2006130843A1 (en) * | 2005-06-02 | 2006-12-07 | Biovail Laboratories International S.R.L. | Modified-release composition of at least one form of venlafaxine |
US20070122824A1 (en) | 2005-09-09 | 2007-05-31 | Tucker Mark R | Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime |
EP1938231A1 (en) | 2005-09-19 | 2008-07-02 | BG Medicine, Inc. | Correlation analysis of biological systems |
RU2318508C2 (ru) * | 2005-12-28 | 2008-03-10 | Всеволод Иванович Киселев | Фармацевтическая композиция для лечения и профилактики пролиферативных заболеваний молочной железы |
FR2896896B1 (fr) | 2006-02-02 | 2009-09-25 | Commissariat Energie Atomique | Procede de classification d'evenements ou d'etats en deux etapes |
DE102006028232A1 (de) | 2006-06-20 | 2007-12-27 | Bayer Technology Services Gmbh | Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis |
US20090291134A1 (en) | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
IN2014MN00139A (da) | 2006-11-21 | 2015-06-19 | Jina Pharmaceuticals Inc | |
US8099298B2 (en) | 2007-02-14 | 2012-01-17 | Genelex, Inc | Genetic data analysis and database tools |
AU2009219228A1 (en) | 2008-02-26 | 2009-09-03 | Purdue Research Foundation | Method for patient genotyping |
WO2009120999A2 (en) * | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
WO2009137543A2 (en) * | 2008-05-06 | 2009-11-12 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
MX366570B (es) | 2008-06-30 | 2019-07-12 | Tocagen Inc | Formulaciones de 5-fluorocitosina y usos de las mismas. |
JP4517312B2 (ja) * | 2008-07-08 | 2010-08-04 | ソニー株式会社 | メモリアクセス制御装置および撮像装置 |
US20110136913A1 (en) * | 2008-08-19 | 2011-06-09 | Goetz Matthew P | Assessing and treating breast cancer patients |
WO2010036732A1 (en) | 2008-09-25 | 2010-04-01 | Zeltiq Aesthetics, Inc. | Treatment planning systems and methods for body contouring applications |
US7873482B2 (en) | 2008-12-16 | 2011-01-18 | Bruno Stefanon | Diagnostic system for selecting nutrition and pharmacological products for animals |
WO2010096834A2 (en) | 2009-02-23 | 2010-08-26 | Indiana University Research & Technology Corporation | Materials and methods for treating patients with tamoxifen |
WO2011072244A1 (en) * | 2009-12-10 | 2011-06-16 | Mount Sinai School Of Medicine Of New York University | Method of treatment of breast cancer with tamoxifen |
US9372198B2 (en) | 2010-06-17 | 2016-06-21 | Aradigm Corporation | Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals |
NZ606903A (en) * | 2010-08-26 | 2015-05-29 | Ipca Lab Ltd | Methods for the treatment or prophylaxis of thrombosis or embolism |
KR20140047082A (ko) * | 2011-06-27 | 2014-04-21 | 아이피시에이 래버러토리즈 리미티드 | 항-혈전 화합물 |
EA038600B1 (ru) | 2012-04-02 | 2021-09-21 | Берг Ллк | Основанные на клетках перекрестные анализы и их применение |
EP2668945A1 (de) | 2012-06-01 | 2013-12-04 | Bayer Technology Services GmbH | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
US9417221B2 (en) | 2013-08-27 | 2016-08-16 | International Business Machines Corporation | Food steganography |
-
2012
- 2012-06-01 EP EP12170401.9A patent/EP2668945A1/de not_active Withdrawn
-
2013
- 2013-05-27 EP EP13725157.5A patent/EP2854789B1/de active Active
- 2013-05-27 AU AU2013269793A patent/AU2013269793B2/en active Active
- 2013-05-27 DK DK13725157.5T patent/DK2854789T3/da active
- 2013-05-27 CN CN201380040850.8A patent/CN104507464A/zh active Pending
- 2013-05-27 MX MX2014014596A patent/MX370304B/es active IP Right Grant
- 2013-05-27 PL PL13725157T patent/PL2854789T3/pl unknown
- 2013-05-27 WO PCT/EP2013/060824 patent/WO2013178565A1/de active Application Filing
- 2013-05-27 SG SG10201610072UA patent/SG10201610072UA/en unknown
- 2013-05-27 PT PT13725157T patent/PT2854789T/pt unknown
- 2013-05-27 BR BR112014030059-3A patent/BR112014030059B1/pt active IP Right Grant
- 2013-05-27 US US14/403,823 patent/US10285958B2/en active Active
- 2013-05-27 SG SG11201407791VA patent/SG11201407791VA/en unknown
- 2013-05-27 CN CN201910317702.5A patent/CN110075097A/zh active Pending
- 2013-05-27 ES ES13725157T patent/ES2744306T3/es active Active
- 2013-05-27 KR KR1020147036212A patent/KR102129043B1/ko active IP Right Grant
- 2013-05-27 JP JP2015514441A patent/JP6096289B2/ja active Active
- 2013-05-27 RU RU2014154140A patent/RU2683260C2/ru active
- 2013-05-27 NZ NZ702849A patent/NZ702849A/en unknown
- 2013-05-27 HU HUE13725157A patent/HUE045699T2/hu unknown
- 2013-05-27 CA CA2875189A patent/CA2875189C/en active Active
- 2013-05-31 TW TW102119266A patent/TWI644666B/zh active
- 2013-05-31 AR ARP130101928 patent/AR091234A1/es unknown
- 2013-06-01 SA SA113340607A patent/SA113340607B1/ar unknown
-
2014
- 2014-11-30 IL IL235988A patent/IL235988B/en active IP Right Grant
-
2015
- 2015-08-17 HK HK15107896.3A patent/HK1207296A1/xx unknown
-
2016
- 2016-11-09 JP JP2016219156A patent/JP2017048234A/ja active Pending
-
2017
- 2017-01-31 US US15/420,733 patent/US20170326080A1/en not_active Abandoned
- 2017-06-16 US US15/625,553 patent/US20170326081A1/en not_active Abandoned
-
2020
- 2020-04-30 AR ARP200101246A patent/AR118842A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2022027I2 (el) | Παραγωγα βενζιμιδαζολο-προλινης | |
DK3181128T3 (da) | Farmaceutisk nilotinib-sammensætning | |
DK3117837T3 (da) | Antistofformuleringer | |
DK3725778T3 (da) | Formuleringer af enzalutamid | |
BR112015006198A2 (pt) | conjunto de cadeira | |
DK2694038T3 (da) | Farmaceutisk sammensætning | |
BR112014003052A2 (pt) | composições farmacêuticas | |
DK2864426T3 (da) | Justerbare materialer | |
BR112015003160A2 (pt) | corantes de azaindolina - cianina substituídos por hidroxamato e bioconjugados dos mesmos | |
GT201200303A (es) | Formulaciones farmacéuticas | |
CO6930367A2 (es) | Composiciones farmaceúticas | |
CO6940426A2 (es) | Formulaciones farmacéuticas | |
CO7020919A2 (es) | Derivados de tetrahidro-quinazolinona | |
DK2903896T3 (da) | Baneindretning | |
DK2897594T3 (da) | Farmaceutisk sammensætning | |
BR112014000015A2 (pt) | formulação | |
DK2815752T3 (da) | Oral farmaceutisk sammensætning | |
CL2014003283A1 (es) | Formulación farmacéutica. | |
BR112014015885A2 (pt) | preparação farmacêutica | |
FR2988426B1 (fr) | Plate-forme inter-aubes | |
FR2988427B1 (fr) | Plate-forme inter-aubes | |
CO7091176A2 (es) | Diagnóstico farmacéutico | |
DK2931042T3 (da) | Anthracyclinformuleringer | |
DK3473255T3 (da) | Farmaceutisk formulering omfattende ciclesonid | |
DK2672817T3 (da) | Forbedrede insekticide formuleringer |